Drugs / Brelovitug
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07454837 | Feb 2026 → Aug 2027 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06907290 | Mar 2025 → May 2029 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07298330 | Jan → Aug 2026 overdue | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07200908 | Aug 2025 → Jun 2027 expected | hepatitis D virus infection | Mirum Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brelovitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07298330 ↗ |
| Known as | BJT-778 | “This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.” NCT06907290 ↗ |
| Known as | BTG | “This is a Phase 2b/3 study designed to evaluate the safety and efficacy of chronic treatment with brelovitug (a.k.a BJT-778; BTG) for chronic hepatitis delta virus (HDV) infection.” NCT06907290 ↗ |
| Route | Subcutaneous | “Route of administration- Subcutaneous Injection” NCT06907290 ↗ |